RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Autoantibodies Predict Treatment Response to Rituximab in Myositis
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 19
SP 14
OP 14
DO 10.1177/155989771219009
UL http://mdc.sagepub.com/content/12/19/14.1.abstract
AB The presence of myositis-associated autoantibodies is the strongest predictor of improvement in patients with adult and juvenile myositis treated with B-cell depletion. This article describes findings from the Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis [RIM] study, in which baseline clinical, laboratory, and serologic predictors of response were examined in rituximab-treated patients with refractory myositis, defined as failure of steroids and at least 1 other immunosuppressive agent.